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1. Introduction 
Dyslipidemia is a powerful predictor of cardiovascular disease in patients at high risk 
(Turner et al., 1998), such as type 2 diabetic patients. Lowering of LDL-C is the prime target 
for treatment (2002), but even with intensification of statin therapy, a substantial residual 
cardiovascular risk remains (Barter et al., 2007; Miller et al., 2008; Fruchart et al., 2008; 
Shepherd et al., 2006). This may partly be due to atherogenic dyslipidemia. This term is 
commonly used to describe a condition of abnormally elevated plasma triglycerides and low 
high-density lipoprotein cholesterol (HDL-C), irrespective of the levels of LDL-C (Grundy, 
1995). In addition to these key components, increased levels of small, dense LDL-C particles 
are also present, which in conjunction with the former components conform the also called 
“lipid triad” (Shepherd et al., 2005). Other abnormalities include accumulation in plasma of 
triglyceride-rich lipoproteins (TLRs), including chylomicron and very-low-density 
lipoprotein (VLDL) remnants. This is reflected by elevated plasma concentrations of non-
HDL-C and apolipoprotein B-100 (apoB). Postprandially, there is also accumulation in 
plasma of TLRs and their remnants, as well as qualitative alterations in LDL and HDL 
particles. Thus, hypertriglyceridemia is associated with a wide spectrum of atherogenic 
lipoproteins not measured routinely (Taskinen, 2003). The presence of this lipid plasma 
profile with high triglyceride and low HDL-C levels have been shown to increase the risk of 
cardiovascular events independent of conventional risk factors (Bansal et al., 2007; Barter et 
al., 2007; deGoma et al., 2008). In fact, guidelines recommend modifying high triglyceride 
and low HDL-C as secondary therapeutic targets to provide additional vascular protection 
(2002). The presence of atherogenic dyslipidemia is seen in almost all patients with 
triglycerides > 2.2 mmol/l and HDL-C < 1.0 mmol/l, virtually all of whom have type 2 
diabetes or abdominal obesity and insulin resistance (Taskinen, 2003). Most of these 
alterations are also characteristic of metabolic syndrome, which is defined as the clustering 
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of multiple metabolic abnormalities, including abdominal obesity, dyslipidemia (high serum 
triglycerides and low serum HDL-C levels), glucose intolerance and hypertension (Eckel et 
al., 2005; Grundy et al., 2005).  
2. Hypertriglyceridemia is crucial in the pathogenesis of atherogenic 
dyslipidemia 
It is now recognized that the atherogenic dyslipidemia is mainly initiated by the hepatic 
overproduction of the plasma lipoproteins carrying triglycerides, the VLDL, which induce a 
sequence of lipoprotein changes leading to atherogenic lipid abnormalities in type 2 
diabetes mellitus and metabolic syndrome (Adiels et al., 2008). Under these pathological 
conditions, the presence of insulin resistance at the level of adipose tissue leads to enhanced 
lypolisis and reduced free fatty acid (FFA) uptake and esterification which results in 
increased flux into the liver of FFA, which are either oxidized or esterified for triglyceride 
production, leading to hepatic steatosis and oversecretion into plasma of larger triglyceride-
rich VLDL particles (Chan & Watts, 2011). These particles compete with chylomicrons and 
its remnants for clearance pathways regulated by lipoprotein lipase, an endothelial-bound 
enzyme, and by hepatic receptors, thereby exacerbating postprandial dyslipidemia. In 
addition, insulin resistance increases hepatic secretion of apoC-III, which is attached to 
VLDL delaying the catabolism of TRLs by inhibiting lipoprotein lipase and binding of 
remnant TRLs to hepatic clearance receptors (Chan & Watts, 2011). Finally, expansion of the 
VLDL triglyceride pool leads to cholesterol depletion and triglyceride enrichment of LDL 
and HDL through cholesteryl ester transfer protein, which facilitates the movement of 
cholesterol esters to VLDL, intermediate-density lipoprotein (IDL) and LDL from cholesterol 
ester rich HDL, leading to the accumulation in plasma of small, dense LDLs and a reduction 
in HDLs (Taskinen, 2003).  
Since residual risk remains even after achieving an optimal LDL-C concentration with 
statins (Barter et al., 2007), probably due to other risk factors, such as high triglycerides, low 
HDL-C levels, defective glucose metabolism and other non-lipid-related risk factors 
(Kannel, 1983; Castelli, 1992; Lorenzo et al., 2010; Cederberg et al., 2010), the development of 
new drugs aimed at improving risk reduction is necessary. Among the new drugs for the 
treatment of the risk factors leading to the residual risk, PPARǃ/ǅ activators might have a 
promising future. Interestingly, PPARǃ/ǅ agonists have been demonstrated to be effective 
raising HDL-C and lowering triglyceride concentrations (Kersten, 2008). In addition to their 
lipid-modifying properties, PPARǃ/ǅ agonists improve insulin resistance, which may also 
confer protection against the development of dyslipidemia (Coll et al., 2010a). This review 
summarizes the effects of PPARǃ/ǅ on dyslipidemia identified during the last few years. 
3. The PPAR family 
PPARs are members of the nuclear receptor superfamily of ligand-activated transcription 
factors that regulate the expression of genes involved in fatty acid uptake and oxidation, 
lipid metabolism and inflammation (Kersten et al., 2000). To be transcriptionally active, 
PPARs need to heterodimerize with the 9-cis retinoic acid receptor (RXR) (NR2B) (Figure 1). 
PPAR-RXR heterodimers bind to DNA-specific sequences called peroxisome proliferator-
response elements (PPREs), consisting of an imperfect direct repeat of the consensus binding 
site for nuclear hormone receptors (AGGTCA) separated by one nucleotide (DR-1). These 
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sequences have been characterized within the promoter regions of PPAR target genes. The 
binding occurs in such a way that PPAR is always oriented to the DNA’s 5’-end, while RXR 
is to the 3’-end. In the absence of ligand, high-affinity complexes are formed between PPAR-
RXR heterodimers and nuclear receptor co-repressor proteins, which block transcriptional 
activation by sequestering the heterodimer from the promoter. Binding of the ligand to 
PPAR induces a conformational change resulting in dissociation of co-repressor proteins, so 
that the PPAR-RXR heterodimer can then bind to PPREs. Moreover, once activated by the 
ligand, the heterodimer recruits co-activator proteins that promote the initiation of 
transcription (Feige et al., 2006). As a consequence of these changes in transcriptional 
activity, binding of ligands to the receptor results in changes in the expression level of 
mRNAs encoded by PPAR target genes. In a specific cellular context, the activity of PPARs 
regulating the transcription of their target genes depends on many factors (relative 
expression of the PPARs, the promoter context of the target gene, the presence of co-
activator and co-repressor proteins, etc.).  
Thus, the transcriptional activity of PPARs is modulated by co-activators and co-repressors 
(Feige et al., 2006). One of the best described PPAR co-activators is PPARǄ coactivator 1 ǂ 
(PGC-1ǂ). Silencing mediator for retinoic and thyroid hormone receptor (SMRT) and the 
nuclear receptor co-repressor (NCoR) are co-repressors that interact with the PPARs in the 
absence of ligands (Zamir et al., 1997). Receptor-interacting protein 140 (RIP140), an 
important metabolic regulator, is another ligand-dependent co-repressor which interacts 
with PPARs.  
Finally, PPAR activity is also regulated at the post-transcriptional level by phosphorylation, 
ubiquitinylation, and sumoylation (for a detailed review see (Feige et al., 2006)). 
However, the regulation of gene transcription by PPARs extends beyond their ability to 
trans-activate specific target genes in an agonist-dependent manner. PPARs also regulate 
gene expression independently of binding to PPREs. They cross-talk with other types of 
transcription factors and influence their function without binding to DNA, through a 
mechanism termed receptor-dependent trans-repression (Daynes & Jones, 2002). Most of the 
anti-inflammatory effects of PPARs are probably explained by this mechanism (Kamei et al., 
1996; Li et al., 2000). Thus, through this DNA-binding independent mechanism, PPARs 
suppress the activities of several transcription factors, including nuclear factor κB (NF-κB), 
activator protein 1 (AP-1), signal transducers and activators of transcription (STATs) and 
nuclear factor of activated T cells (NFAT). There are three main trans-repression 
mechanisms by which ligand-activated PPAR-RXR complexes negatively regulate the 
activities of other transcription factors. First, trans-repression may result from competition 
for limiting amounts of shared co-activators. Under conditions in which the levels of specific 
co-activators are rate-limiting, activation of PPAR may suppress the activity of other 
transcription factors that use the same co-activators (Delerive et al., 1999; Delerive et al., 
2002). In the second mechanism, activated PPAR-RXR heterodimers are believed to act 
through physical interaction with other transcription factors (for example AP-1, NF-κB, 
NFAT or STATs). This association prevents the transcription factor from binding to its 
response element and thereby inhibits its ability to induce gene transcription (Desreumaux 
et al., 2001). The third trans-repression mechanism relies on the ability of activated PPAR-
RXR heterodimers to inhibit the phosphorylation and activation of certain members of the 
mitogen-activated protein kinase (MAPK) cascade (Johnson et al., 1997), preventing 
activation of downstream transcription factors. 
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The PPAR family consists of three members, PPARǂ (NR1C1 according to the unified 
nomenclature system for the nuclear receptor superfamily), PPARǃ/ǅ (NR1C2) and PPARǄ 
(NR1C3) (Auwerx et al., 1999). PPARǂ was the first PPAR to be identified and is the 
molecular target of the fibrate hypolipidemic class of drugs. This PPAR isotype is expressed 
primarily in tissues with a high level of fatty acid catabolism such as liver, brown fat, 
kidney, heart and skeletal muscle (Braissant et al., 1996). PPARǄ has a restricted pattern of 
expression, mainly in white and brown adipose tissues and macrophages, whereas other 
tissues such as skeletal muscle and heart contain limited amounts. The Ǆ isotype is the 
molecular target for the anti-diabetic drugs, thiazolidinediones. PPARǃ/ǅ is ubiquitously 
expressed and, for this reason, was initially thought to be a “housekeeping gene” (Kliewer et 
al., 1994). However, studies with knockout mice (Barak et al., 2002; Peters et al., 2000; Tan et 
al., 2001) and the development of specific and high-affinity ligands for this receptor have 
shown that PPARǃ/ǅ is a potential molecular target for prevention or treatment of several 
disorders. In this review we will highlight the role of PPARǃ/ǅ in those metabolic processes 
with potential for treating dyslipidemia. 
 
 
Fig. 1. Molecular mechanisms of Peroxisome Proliferator-Activated Receptors (PPARs). 
PPARs are ligand-activated transcription factors that regulate gene expression through two 
mechanisms: transactivation and transrepression. In transactivation PPAR-RXR 
heterodimers bind to DNA-specific sequences called peroxisome proliferator-response 
elements (PPREs), which are located in the promoter regions of genes involved in glucose 
and fatty acid metabolism. PPARs may also regulate gene expression through a DNA-
independent mechanism called transrepression. Through this mechanism, PPARs inhibit the 
activity of several transcription factors such as NF-κB, which leads to anti-inflammatory 
effects. STAT denotes signal transducers and activators of transcription. 
4. PPARβ/δ-specific features and ligands 
The crystal structure of the ligand-binding domain of the PPARǃ/ǅ isotype, which was 
first cloned in Xenopus laevis (Dreyer et al., 1992), revealed an exceptionally large pocket of 
approximately 1300 Å3. This pocket is similar to that of PPARǄ, but much larger than the 
pockets of other nuclear receptors (Takada et al., 2000; Xu et al., 1999), which may explain, 
at least in part, the great variety of natural and synthetic ligands that bind to and activate 
this nuclear receptor. Saturated (14 to 18 carbons) and polyunsaturated (20 carbons in 
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length) fatty acids have affinities for PPARǃ/ǅ in the low micromolar range (Xu et al., 
1999; Forman et al., 1997; Yu et al., 1995; Krey et al., 1997). In addition, all-trans-retinoic 
acid (vitamin A) (Shaw et al., 2003) and fatty acids derived from VLDL (Chawla et al., 
2003) can activate PPARǃ/ǅFinally, the availability of three synthetic ligands (GW501516, 
GW0742 and L-165041) that activate PPARǃ/ǅ at very low concentrations both in vivo 
and in vitro with high selectivity over other PPAR isotypes (Sznaidman et al., 2003) led to 
a huge increase in experimental studies on the role of PPARǃ/ǅ in cellular processes. The 
EC50 for these compounds assessed with recombinant human PPARǃ/ǅ were 1.0 nM for 
GW0742, 1.1 nM for GW501516 and 50 nM for L-165041 (Berger et al., 1999; Sznaidman et 
al., 2003).  
5. Role of PPARβ/δ in lipoprotein metabolism  
Treatment of the atherogenic dyslipidemia associated with type 2 diabetes mellitus and 
metabolic syndrome requires lowering triglycerides, increasing HDL-C and increasing the 
size of the LDL-C particle. Studies using the PPARǃ/ǅ agonist GW501516 have 
demonstrated that this drug increased HDL-C (79%), and decreased triglycerides (56%), 
LDL-C (29%) and fasting insulin levels (48%) in obese rhesus monkeys, a model for human 
obesity and its associated metabolic disorders (Oliver, Jr. et al., 2001). A decrease in small 
dense LDL was also observed in treated animals (Oliver, Jr. et al., 2001). It has been 
suggested that the increase in HDL-C levels after PPARǃ/ǅ treatment is caused by enhanced 
cholesterol efflux stimulated by a higher expression of the reverse cholesterol transporter 
ATP-binding cassette A1 (ABCA1) in several tissues, including human and mouse 
macrophages and intestinal cells and fibroblasts (Leibowitz et al., 2000; van, V et al., 2005). 
Apart from these beneficial effects of PPARǃ/ǅ activation on HDL levels, treatment with 
this compound also increased HDL particle size in primates (Wallace et al., 2005), an effect 
which is thought to be protective against the progression of coronary artery disease in 
humans (Rosenson et al., 2002). In addition, PPARǃ/ǅ activation reduces cholesterol 
absorption through a mechanism that may involve, at least in part, reduced intestinal 
expression of Niemann-Pick C1-like 1 (Npc1l1), the proposed target for the inhibitor of 
cholesterol absorption ezetimibe (van, V et al., 2005). However, additional studies are 
necessary to clearly demonstrate that the effects of these drugs are mediated through 
PPARǃ/ǅ activation.  
In obese and diabetic db/db mice, administration of a PPARǃ/ǅ agonist modestly increased 
HDL particles, without affecting triglyceride levels (Leibowitz et al., 2000), whereas in a 
shorter treatment with GW501516 a reduction in plasma free fatty acids and triglyceride 
levels was observed in db/db mice, but not in mice exposed to a high fat diet (Tanaka et al., 
2003).  
In mice, deletion of PPARǃ/ǅ  led to enhanced LDL and triglyceride levels (Akiyama et al., 
2004). It has been proposed that the increase in triglycerides observed in these PPARǃ/ǅ-
null mice is caused by a combination of increased VLDL production and decreased plasma 
triglyceride clearance, as demonstrated by a decrease in postheparin LPL activity and 
increased hepatic expression of the LPL inhibitors Angptl3 and 4 (Akiyama et al., 2004). 
Recent findings obtained by our laboratory indicate that additional mechanisms can also 
contribute to the hypotriglyceridemic effect of PPARǃ/ǅ (Barroso et al., 2011). Interestingly, 
the main factor influencing hepatic triglyceride secretion is fatty acid availability (Lewis, 
1997). In liver, fatty acids are either incorporated into triglycerides or oxidized by 
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mitochondrial -oxidation. An increase in fatty acid oxidation in liver would thus reduce the 
availability of fatty acids and subsequent hepatic triglyceride secretion. However, it was 
unknown whether the hypotriglyceridemic effect observed following PPAR/ activation 
involved increased hepatic fatty acid oxidation and the mechanisms implicated. The rate-
limiting step for mitochondrial -oxidation is the transport of fatty acid into mitochondria 
by liver carnitine palmitoyltransferase-1 (CPT1a). This fatty acid transporter is under the 
control of both PPARs and AMP-activated protein kinase (AMPK), which detects low ATP 
levels and in turn increases oxidative metabolism (Zhang et al., 2009) by reducing the levels 
of malonyl-CoA. Interestingly, PPAR/ activation can increase the activity of AMPK and 
the increase in fatty acid oxidation in human skeletal muscle cells following GW501516 
treatment is dependent on both PPAR/ and AMPK (Kramer et al., 2007). It is worth 
noting that a recent discovered protein, lipin 1, plays an important role in hepatic fatty acid 
oxidation since it determines whether fatty acids are incorporated into triglycerides or 
undergo mitochondrial -oxidation. In addition, the expression and compartmentalization 
of lipin 1 controls the secretion of hepatic triglycerides (Bou et al., 2009). Thus, in the 
cytoplasm, lipin 1 promotes triglyceride accumulation and phospholipid synthesis by 
functioning as an Mg2+-dependent phosphatidate phosphatase (phosphatidic acid 
phosphatase-1, PAP-1). In contrast, in the nucleus lipin 1 acts as a transcriptional co-
activator linked to fatty acid oxidation by regulating the induction of PGC-1ǂ-PPARǂ-target 
genes (Finck et al., 2006). Lipin 1 induces PPARǂ gene expression and forms a complex with 
PPARǂ and PGC-1ǂ leading to the induction of genes involved in fatty acid oxidation, 
including Cpt1a and Mcad (medium chain acyl-CoA dehydrogenase ) (Finck et al., 2006). 
When we examined the effects a high-fat diet (HFD) on hypertriglyceridemia and on the 
hepatic fatty acid oxidation pathway, we observed that exposure to HFD caused 
hypertriglyceridemia that was accompanied by reduced hepatic mRNA levels of PGC-1ǂ 
and lipin 1, reduced hepatic phospho-AMPK levels and increased activity of extracellular-
signal-regulated kinase 1/2 (ERK1/2) (Figure 2). Interestingly, drug treatment reduced 
hypertriglyceridemia, and restored hepatic phosphorylated levels of AMPK and ERK1/2. 
GW501516 treatment increased nuclear lipin 1 protein levels, leading to amplification of the 
PGC-1ǂ-PPARǂ signaling system, as demonstrated by the increase in PPARǂ levels and 
PPARǂ-DNA binding activity and the increased expression of PPARǂ-target genes involved 
in fatty acid oxidation. These effects of GW501516 were accompanied by an increase in 
plasma -hydroxybutyrate levels, demonstrating enhanced hepatic fatty acid oxidation. 
The maintenance of AMPK phosphorylation following GW501516 treatment was 
accompanied by the recovery in the expression levels of Lipin 1 and Pgc-1ǂ and the increase 
in the mRNA levels of the Vldl receptor (Figure 2). Although we cannot rule out direct 
transcriptional activation of these genes by PPARǃ/ǅ since it has been suggested that Lipin 
1, the Vldl receptor (Sanderson et al., 2010) and Pgc-1ǂ (Hondares et al., 2007) might be 
PPARǃ/ǅ-target genes, most effects of GW501516 might be the result of the increase in 
AMPK phosphorylation (Kramer et al., 2007). In fact, it has been reported that this kinase 
upregulates the expression of Lipin 1 (Higashida et al., 2008), the Vldl receptor (Zenimaru et 
al., 2008) and Pgc-1ǂ (Lee et al., 2006b). The increase in AMPK phosphorylation following 
GW501516 treatment might involve several mechanisms. Since inhibitory crosstalk between 
ERK1/2 and AMPK has been reported (Du et al., 2008), the increase in phospho-AMPK 
levels could be the result of the inhibition by GW501516 of the phosphorylation of ERK1/2 
induced by the HFD, which is in agreement with our previous study reporting that 
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GW501516 prevents LPS-induced ERK1/2 phosphorylation in adipocytes (Rodriguez-Calvo 
et al., 2008). It is important to note that a previous study found that obesity leads to 
increased hepatic ERK1/2 activity and that caloric restriction blunts this increase and 
improves insulin sensitivity (Zheng et al., 2009). In our study, the improvement in glucose 
tolerance caused by GW501516 was also accompanied by the reduction in phospho-ERK1/2 
levels. An additional mechanism could involve SIRT1, since it has recently been reported 
that pharmacological PPARǃ/ǅ activation increases the expression of SIRT1 (Okazaki et al., 
2010), a deacetylase which regulates AMPK activity (Ruderman et al., 2010) through LKB1 
acetylation (Lan et al., 2008), and might be essential to the regulatory loop involving PPARǂ, 
PGC-1ǂ and Lipin 1 (Sugden et al., 2010). However, our findings made this possibility 
unlikely given that the increase in SIRT1 levels induced by GW501516 did not modify the 
acetylation status of LKB1. Interestingly, we showed that GW501516 increased the 
AMP/ATP ratio in liver, indicating that, in line with a previous study in skeletal muscle 
cells (Kramer et al., 2007), the underlying mechanism responsible for the increase in AMPK 
phosphorylation induced by this drug could be a modification of the cellular energy status. 
Previous studies have suggested that the reduction in ATP levels caused by GW501516 can 
be the result of a specific inhibition of one or more complexes of the respiratory chain, an 
effect on the ATP synthase system, or to mitochondrial uncoupling (Kramer et al., 2007). 
These potential changes would reduce the yield of ATP synthesis by the mitochondria, 
leading to AMPK activation.  
In agreement with the reported regulation of PGC-1ǂ (Canto et al., 2009; Jeninga et al., 2010; 
Lee et al., 2006a) and Lipin 1 (Higashida et al., 2008) by AMPK, exposure to the HFD 
reduced both Pgc-1ǂ and Lipin 1 expression. The reduction in Lipin 1 was likely to be the 
result of the decrease of PGC-1ǂ, since it has been reported that genetic reduction of hepatic 
PGC-1ǂ decreases the expression of Lipin 1 (Estall et al., 2009). In addition, it has been 
shown that physiological stimuli that increase mitochondrial fatty acid oxidation induce 
Pgc-1ǂ gene expression, which in turn activates the expression of Lipin 1 (Finck et al., 2006). 
Interestingly, it has been reported that upregulation of Lipin 1 in liver increases PPARǂ 
activity by two mechanisms: transcriptional activation of the Pparα gene and direct 
coactivation of PPARǂ in cooperation with PGC-1ǂ (Finck et al., 2006). Thus, Lipin 1 is 
considered to be an inducible “booster” that amplifies pathways downstream PGC-1ǂ-
PPARǂ, mainly mitochondrial fatty acid oxidation (Finck et al., 2006). In agreement with 
this, GW501516 treatment prevented the reduction in PGC-1ǂ, increased the nuclear protein 
levels of Lipin 1 and amplified the PGC-1ǂPPARǂ pathway, as demonstrated by the 
increase in the transcriptional activation of Pparǂ and the increase in PPARǂ transcriptional 
activity. These effects subsequently enhanced hepatic fatty acid oxidation, as shown by the 
increase in -hydroxybutyrate levels. The reduction in PGC-1ǂ and Lipin 1 levels caused by 
the HFD and their restoration after GW501516 treatment observed in our study might also 
contribute to the changes of plasma triglyceride levels, since both proteins are involved in 
the control of hepatic triglyceride secretion and fatty acid oxidation (Zhang et al., 2004; Chen 
et al., 2008; Estall et al., 2009). Overall, these data implicated PGC-1ǂ and Lipin 1 in the 
hypotriglyceridemic effect of PPARǃ/ǅ  and complemented the findings of a previous study 
reporting that elevated plasma triglyceride levels in PPARǃ/ǅ-null mouse were related to a 
combination of increased VLDL production and decreased plasma triglyceride clearance 
(Akiyama et al., 2004). 
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Fig. 2. A schematic of the potential effects of GW501516 (dashed lines) on liver metabolism 
is shown. Drug treatment with the PPAR/ agonist GW501516 prevents the reduction in 
phospho-AMPK levels and the subsequent increase in phospho-ERK1/2 levels caused by 
the HFD. In addition, GW501516 prevents the reduction in PGC-1ǂ and increases Lipin 1 
protein levels in the nucleus leading to amplification of the PPARǂ-PGC-1ǂ pathway, which 
subsequently induces hepatic fatty acid oxidation. This pathway is additionally increased by 
GW501516 through the enhanced synthesis of the hepatic PPARǂ endogenous ligand 
16:0/18:1-PC. As a result of the increase in this pathway the availability of fatty acids to be 
secreted as triglycerides might be compromised. The increase in the hepatic levels of the 
Vldl receptor can also contribute to reduce plasma triglyceride levels.  
The data reported in our study also demonstrated that PPARǃ/ǅ activation by GW501516 
can amplify the PPARǂ pathway by an additional mechanism. Previous studies had 
demonstrated that hepatic fatty acid synthase (FAS) was necessary for the normal activation 
of PPARǂ target genes but did not identify the ligand involved in this process 
(Chakravarthy et al., 2005). Recently, this endogenous PPARǂ ligand was identified as 
16:0/18:1-phosphatidilcholine (PC) (Chakravarthy et al., 2009). The synthesis of this ligand 
requires FAS activity, which yields palmitate (16:0), whereas 16:0/18:1-PC is generated 
through the enzymatic activity of CEPT1 (Chakravarthy et al., 2009). Subsequent binding of 
16:0/18:1-PC to PPARǂ in the nucleus turns on PPARǂ-dependent genes and affects hepatic 
lipid metabolism. Interestingly, activation of PPARǃ/ǅ by GW501516 induces FAS 
expression in liver as a result of increased glycolysis and the pentose phosphate shunt (Lee 
et al., 2006a). Our findings confirmed that GW501516 also increased Cept1 expression and 
the levels of 16:0/18:1-PC, contributing to further amplification of the PPARǂ pathway.  
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The increase in fatty acid oxidation caused by GW501516 was apparently inconsistent with 
its lack of effects on hepatic triglyceride levels observed in our study. Several reasons may 
account for this. First, similar to the effects of GW501516, which restores Lipin 1 levels, 
hepatic Lipin 1 overexpression leads to increased liver triglyceride content (Finck et al., 
2006). This apparently conflicts with the effects of Lipin 1 on fatty acid oxidation, but it has 
been explained by hepatic triglyceride sequestration secondary to diminished triglyceride 
secretion, increased fatty acid uptake, or the PAP activity of Lipin 1 (Finck et al., 2006). 
Second, in our study we reported an additional possibility, the increase caused by 
GW501516 in the expression of the Vldl receptor in liver. The huge increase of this receptor 
observed in liver after GW501516 treatment might also reduce plasma triglyceride levels by 
increasing VLDL uptake by the liver. However, this can also lead to an increase in hepatic 
triglyceride content. Third, it has been reported that GW501516 improves hyperglycemia by 
increasing glucose flux through the pentose phosphate pathway and enhancing fatty acid 
synthesis in liver (Lee et al., 2006a). In that study, GW501516 increased liver triglyceride 
content but the authors reported that although this might raise concerns that long-term drug 
treatment might cause hepatic steatosis, they did not observe signs of fatty liver with 
treatment up to 6 months. In addition, long-term GW501516 treatment has been shown to 
reduce body weight and levels of circulating and liver triglycerides (Wang et al., 2004; 
Tanaka et al., 2003). In summary, our findings indicated that PPAR/ activation by 
GW501516 amplified the PPARǂ-PGC1-ǂ pathway through the restoration of AMPK 
activity, contributing to the hypotriglyceridemic effect of this drug. 
In humans, there are conflicting reports as to whether PPARǃ/ǅ polymorphisms are 
associated with changes in plasma lipoproteins. Thus, while some studies found an 
association between a PPARǃ/ǅ polymorphism and plasma lipids (Skogsberg et al., 2003), 
this was not confirmed in other studies (Gouni-Berthold et al., 2005). These discrepancies 
could be caused by differences in gender or the influence of gene-environment interactions, 
since a recent study reported that the association between the PPARǃ/ǅ -87T>C 
polymorphism and plasma HDL-cholesterol might be sex-specific, women showing a 
stronger association, and that this association was only observed in subjects consuming a 
low-fat diet (Robitaille et al., 2007). The authors of this study concluded that the presence of 
the PPARǃ/ǅ -87T>C polymorphism, which may result in enhanced PPARǃ/ǅ activity, is 
associated with lower risk of suffering metabolic syndrome and that this association 
depends on the amount of fat consumed. In summary, the findings available at present on 
the effects of PPARǃ/ǅ activation on lipoprotein metabolism are so promising that 
PPARǃ/ǅ drugs are now in clinical trials for the treatment of human dyslipidemia.  
6. Role of PPARβ/δ in insulin resistance 
As stated above insulin resistance plays a crucial role in the development of 
hypertrigliceridemia, resulting in a sequence of lipoprotein changes leading to atherogenic 
dyslipidemia. Thus, those drugs, such as the PPARǃ/ǅ ligands, which improve insulin 
resistance may also contribute to ameliorate the atherogenic dyslipidemia. 
6.1 PPARβ/δ, inflammation and insulin resistance in adipose tissue 
The expansion of adipose tissue, mainly in the form of visceral obesity, may contribute to 
enhanced inflammation in this tissue and insulin resistance through several processes. First, 
macrophages can infiltrate in adipose tissue, which contributes to the overproduction of 
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inflammatory cytokines, such as tumor necrosis factor ǂ (TNF-ǂ and interleukin 6 (IL-6) 
(Gustafson et al., 2009). Indeed, the infiltration of macrophages into adipose tissue correlates 
with the degree of insulin resistance (Mathieu et al., 2010). Second, as visceral fat (which is 
very sensitive to lipolytic stimuli) increases, so does the rate of lipolysis. This leads to 
increased free fatty acid (FFA) mobilization and elevated levels of circulating FFA. Several 
studies have consistently demonstrated that elevations of plasma FFA produce insulin 
resistance in diabetic patients and in nondiabetic subjects (Boden et al., 1991; Boden, 1997). 
Saturated FFA are potent activators of the Toll-like receptor-4 (TLR4) (Mathieu et al., 2006) 
and recent evidence suggests that inflammatory processes induced by obesity and a high-fat 
diet cause systemic insulin resistance via a mechanism involving this receptor (Shi et al., 
2006). TLR-4 is expressed in virtually all human cells and binds a wide spectrum of 
exogenous and endogenous ligands, including bacterial lipopolysaccharide (LPS) (Akira et 
al., 2006). In the presence of LPS, the TLR4 complex (including CD-14 and an accessory 
protein, MD-2), recruits the adaptor protein, myeloid differentiation factor-88 (MyD88), 
which in turn recruits interleukin-1 receptor-associated kinase (IRAK). This leads to the 
activation of the pro-inflammatory transcription factor NF-κB (Shoelson et al., 2006) and the 
subsequent enhanced expression of several inflammatory mediators (including IL-6 and 
monocyte chemoattractant protein-1 [MCP-1]). These observations indicate that saturated 
FFA derived from adipocytes and from high-fat diets activate TLR and the inflammatory 
pathway in adipocytes and macrophages, which contribute to the synthesis and production 
of cytokines such as TNF-ǂ (Nguyen et al., 2007). In addition, high-fat diets raise plasma 
LPS to a concentration that is high enough to increase body weight, fasting glycemia and 
inflammation (Cani et al., 2007). Furthermore, LPS receptor-deleted mice (CD14 mutants) 
are hypersensitive to insulin, and the development of insulin resistance, obesity and 
diabetes in this animal model is delayed in response to a high-fat diet (Cani et al., 2007). 
Experiments performed in our laboratory have demonstrated that the PPARǃ/ǅ agonist 
GW501516 inhibits LPS-induced cytokine expression and secretion by preventing NF-κB 
activation in adipocytes (Rodriguez-Calvo et al., 2008). Of note, NF-κB activation by LPS 
requires mitogen-activated protein kinase (MAPK)–extracellular signal–related kinase 
(ERK)1/2 (MEK1/2) activation, since inhibition of this pathway reduces LPS-induced 
cytokine production in adipocytes (Chung et al., 2006). In agreement with this role of 
ERK1/2 in inflammation in adipocytes, the expression of pro-inflammatory cytokines in 
these cells drops when they are exposed to LPS in the presence of the MAPK pathway 
inhibitor U0126. Interestingly, in white adipose tissue from PPARǃ/ǅ-null mice we 
observed increased ERK1/2 phosphorylation and NF-κB activity and higher expression of 
IL-6 compared with wild-type mice (Rodriguez-Calvo et al., 2008). Moreover, in the white 
adipose tissue of a genetic model of obesity and diabetes, the Zucker diabetic fatty (ZDF) 
rat, the reduction in the expression of PPARǃ/ǅ correlated with an increase in ERK1/2 
phosphorylation and NF-κB activity. These findings suggest that PPARǃ/ǅ activation 
prevents LPS-induced NF-κB activation via ERK1/2, thereby reducing the production of 
pro-inflammatory cytokines involved in the development of insulin resistance.  
In addition, it has been suggested that IL-6 is another of the mediators linking obesity-
derived chronic inflammation with insulin resistance through activation of signal transducer 
and activator of transcription 3 (STAT3), with subsequent up-regulation of suppressor of 
cytokine signaling 3 (SOCS3). Recently we have demonstrated that the PPARǃ/ǅ agonist 
GW501516 prevents both IL-6-dependent reduction in insulin-stimulated Akt 
phosphorylation and glucose uptake in adipocytes (Serrano-Marco et al., 2011). In addition, 
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this drug treatment abolished IL-6-induced SOCS3 expression in differentiated 3T3-L1 
adipocytes. This effect was associated with the capacity of the drug to prevent IL-6-induced 
STAT3 phosphorylation on Tyr705 and Ser727 residues in vitro and in vivo. Moreover, 
GW501516 prevented IL-6-dependent induction of ERK1/2, a serine-threonine-protein 
kinase involved in serine STAT3 phosphorylation. Furthermore, in white adipose tissue 
from PPARǃ/ǅ-null mice, STAT3 phosphorylation (Tyr705 and Ser727), STAT3 DNA-binding 
activity and SOCS3 protein levels were higher than in wild-type mice. Several steps in 
STAT3 activation require its association with heat shock protein 90 (Hsp90), which was 
prevented by GW501516 as revealed in immunoprecipitation studies. Consistent with this 
finding, the STAT3-Hsp90 association was enhanced in white adipose tissue from 
PPARǃ/ǅ-null mice compared to wild-type mice. Collectively, our findings indicate that 
PPARǃ/ǅ activation prevents IL-6-induced STAT3 activation by inhibiting ERK1/2 and 
preventing the STAT3-Hsp90 association, an effect that may contribute to the prevention of 
cytokine-induced insulin resistance in adipocytes. 
6.2 PPARβ/δ, inflammation and insulin resistance in skeletal muscle cells 
FFAs may cause insulin resistance in skeletal muscle through several mechanisms, including 
effects on metabolism (Roden et al., 1996; Haber et al., 2003), signaling (Hirabara et al., 2007; 
Silveira et al., 2008) and mitochondrial function (Schrauwen et al., 2010; Hirabara et al., 
2010). In addition, FFAs activate pro-inflammatory pathways, linking the development of 
this pathology to a chronic low-grade systemic inflammatory response (Wellen & 
Hotamisligil, 2005). In addition to FFA-induced inflammation through TLR, an additional 
pathway leads to FFA-mediated inflammation. This pathway involves intracellular 
accumulation of fatty acid derivatives. Once fatty acids are taken up by skeletal muscle cells 
they are either stored as fatty acid derivatives or undergo ǃ-oxidation in the mitochondria. 
In the presence of high plasma FFA, fatty acid flux in skeletal muscle cells exceeds its 
oxidation, which leads to the accumulation of fatty acid derivatives, such as diacylglycerol 
(DAG), which can then activate a number of different serine kinases that negatively regulate 
insulin action. Thus, DAG is a potent allosteric activator of protein kinase Cθ (PKCθ), which 
is the most abundant PKC isoform in skeletal muscle (Griffin et al., 1999; Cortright et al., 
2000; Itani et al., 2000). This PKC isoform inhibits the action of insulin by phosphorylating 
certain serine residues on insulin receptor substrate 1 (IRS1), including Ser307 in the rodent 
IRS-1 protein (reviewed in ref. (Gual et al., 2005)). This phosphorylation impairs insulin-
receptor signaling through several distinct mechanisms (Hotamisligil et al., 1996). PKC also 
impairs insulin sensitivity by activating another serine kinase, IκB kinase ǃ (IKKǃ) 
(Perseghin et al., 2003). In addition to phosphorylating IRS-1 in Ser307, IKKǃ phosphorylates 
IκB. Thus, it activates the pro-inflammatory transcription factor NF-κB, which has been 
linked to fatty acid-induced impairment of insulin action in skeletal muscle in rodents (Kim 
et al., 2001; Yuan et al., 2001). Once activated, NF-κB regulates the expression of multiple 
inflammatory mediators, including IL-6. This cytokine correlates strongly with insulin 
resistance and type 2 diabetes (Pickup et al., 1997; Kern et al., 2001; Pradhan et al., 2001) and 
its plasma levels are 2-3 times higher in patients with obesity and type 2 diabetes than in 
lean control subjects (Kern et al., 2001). 
Accumulation of fatty acid derivatives can be attenuated by mitochondrial ǃ-oxidation. The 
rate-limiting step for ǃ-oxidation of long-chain fatty acids is their transport into 
mitochondria via CPT-1. The activity of this enzyme is inhibited by malonyl-CoA, the 
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product of acetyl-CoA carboxylase, which, in turn, is inhibited by AMPK. This kinase is a 
metabolic sensor that detects low ATP levels and increases oxidative metabolism (Reznick & 
Shulman, 2006), by reducing the levels of malonyl-CoA. Interestingly, activation of fatty acid 
oxidation by overexpressing CPT-1 in cultured skeletal muscle cells (Sebastian et al., 2007) 
and in mouse skeletal muscle (Bruce et al., 2009) improves lipid-induced insulin resistance. 
Hence, this approach may provide a valid therapeutic strategy to prevent this pathology. 
Activation of PPARǃ/ǅ by its ligands (including GW501516) enhances fatty acid catabolism 
in adipose tissue and skeletal muscle, thereby delaying weight gain (for a review see (Barish 
et al., 2006)). This increase in fatty acid oxidation in human skeletal muscle cells following 
PPARǃ/ǅ activation by GW501516 is dependent on both PPARǃ/ǅ and AMPK (Kramer et 
al., 2007). AMPK is activated by GW501516 by modulating the ATP:AMP ratio (Kramer et 
al., 2007). Despite these data, little information was available on whether the increase in fatty 
acid oxidation attained after PPARǃ/ǅ activation prevented fatty acid-induced 
inflammation and insulin resistance in skeletal muscle cells. However, we have recently 
reported that the PPARǃ/ǅ ligand GW501516 prevented palmitate-induced inflammation 
and insulin resistance in skeletal muscle cells (Coll et al., 2010b). Treatment with GW501516 
enhanced the expression of two-well known PPARǃ/ǅ-target genes involved in fatty acid 
oxidation, CPT-1 and pyruvate dehydrogenase kinase 4 (PDK-4), and increased the 
phosphorylation of AMPK. This prevented the reduction in fatty acid oxidation caused by 
palmitate exposure. In agreement with these changes, GW501516 treatment reversed the 
increase in DAG and PKCθ activation caused by palmitate. These effects were abolished in 
the presence of the CPT-1 inhibitor etomoxir, thereby implicating increased fatty acid 
oxidation in the changes. Consistent with these findings, PPARǃ/ǅ activation by GW501516 
blocked palmitate-induced NF-κB DNA-binding activity. Likewise, drug treatment inhibited 
the increase in IL-6 expression caused by palmitate in C2C12 myotubes and human skeletal 
muscle cells, as well as the protein secretion of this cytokine. Overall, these findings indicate 
that PPARǃ/ǅ attenuates fatty acid-induced NF-κB activation and the subsequent 
development of insulin resistance in skeletal muscle cells by reducing DAG accumulation. 
Interestingly, it has been suggested that the hypotrigliceridemic effect of GW501516 in 
humans is dependent of the increase in CPT-1 expression observed in skeletal muscle 
(Riserus et al., 2008). 
7. Conclusion 
Reduction of LDL-C, the main target of hypolipidemic therapy, has been proved effective 
reducing morbidity and mortality associated to CVD. However, a high proportion of 
patients receiving statins, the most lipid-lowering family of drugs used, do not reach 
optimal LDL-C levels. In addition, even in those patients reaching the optimal LDL-C levels 
following statin treatment, a residual risk remains, probably due to the presence of other 
risk factors, including the presence of atherogic dyslipidemia (described by the presence of 
high triglycerides, low HDL-C levels, and the presence of small dense LDL particles), 
glucose metabolism alterations and additional non-lipid-related risk factors. Several studies 
have confirmed that PPARǃ/ǅ plays an important role in the regulation of lipoprotein 
metabolism, leading to reductions in the levels of plasma triglycerides and LDL-C and 
increases in HDL-C in different animal models. Taken together, these effects attained 
following PPARǃ/ǅ activation on lipoprotein metabolism are so promising that this nuclear 
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receptor has been considered a therapeutic target to prevent and treat dyslipidemia. 
However, as with any drug designed for human therapy, a great deal of research will be 
needed on the efficacy and safety of PPARǃ/ǅ activators before they reach clinical use.  
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